From the Levine Cancer Institute, Atrium Health, Charlotte, NC.
Cancer J. 2021;27(1):50-58. doi: 10.1097/PPO.0000000000000495.
Triple-negative breast cancer is increasingly recognized as a heterogeneous entity that can be categorized according to histologic, molecular, and clinical subtypes. While chemotherapy remains the backbone of treatment for this disease, there are now several available targeted agents including immunotherapy, poly(adenosine diphosphate-ribose) polymerase inhibitors, and most recently a Food and Drug Administration-approved antibody-drug conjugate sacituzumab govitecan-hziy as a third-line treatment of metastatic triple-negative breast cancer. We review several actionable targets for triple-negative breast cancer and describe promising nonimmunotherapeutic agents including cyclin-dependent kinase inhibitors, androgen receptor inhibitors, mitogen-activated protein kinase inhibitors, phosphoinositide 3-kinase inhibitors, AKT (also known as protein kinase B) inhibitors, and antibody-drug conjugates.
三阴性乳腺癌越来越被认为是一种异质性实体，可以根据组织学、分子和临床亚型进行分类。虽然化疗仍然是治疗这种疾病的基础，但现在有几种可用的靶向药物，包括免疫疗法、聚（腺嘌呤二核苷酸核糖）聚合酶抑制剂，以及最近美国食品和药物管理局批准的抗体药物偶联物 sacituzumab govitecan-hziy，作为转移性三阴性乳腺癌的三线治疗药物。我们回顾了三阴性乳腺癌的几个可操作靶点，并描述了一些有前途的非免疫治疗药物，包括细胞周期蛋白依赖性激酶抑制剂、雄激素受体抑制剂、丝裂原活化蛋白激酶抑制剂、磷酸肌醇 3-激酶抑制剂、AKT（也称为蛋白激酶 B）抑制剂和抗体药物偶联物。
